tert-butyl 1-methyl-3-nitro-1H-pyrazol-5-ylcarbamate | 948573-72-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: tert-butyl 1-methyl-3-nitro-1H-pyrazol-5-ylcarbamate
• 英文别名: 3-nitro-5-(N-tert-butoxycarbonylamino)-1-methylpyrazole；tert-butyl (1-methyl-3-nitro-1H-pyrazol-5-yl)carbamate；tert-butyl N-(2-methyl-5-nitropyrazol-3-yl)carbamate
• CAS: 948573-72-6
• 化学式: C₉H₁₄N₄O₄
• 分子量: 242.235
• InChiKey: BSRAUZBMAOXPMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 1-methyl-3-nitro-1H-pyrazol-5-ylcarbamate 在 platinum(IV) oxide 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 tert-butyl 3-amino-1-methyl-1H-pyrazol-5-ylcarbamate
  参考文献：
  名称：

  WO2007/99326

  摘要：

  公开号：
• 作为产物：
  描述：

  1-甲基-3-硝基吡唑-5-羧酸 、 叔丁醇 在 二苯基膦叠氮化物 作用下， 反应 6.5h， 以65%的产率得到tert-butyl 1-methyl-3-nitro-1H-pyrazol-5-ylcarbamate
  参考文献：
  名称：

  Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.

  DOI：

  10.1021/jm400822z

文献信息

• QUINOLINE DERIVATIVES
  申请人：Jung Frederic Henri

  公开号：US20090076074A1

  公开（公告）日：2009-03-19

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及公式I的喹啉衍生物或其药学上可接受的盐，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有在本说明书中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于治疗细胞增殖性疾病的药物的过程中的使用。
• US7973164B2
  申请人：——

  公开号：US7973164B2

  公开（公告）日：2011-07-05